Q-omics provides the consensus-scored MIR6859-4 profile across patient tissues and cancer cell-line models. MIR6859-4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR6859-4 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, MIR6859-4 RNA expression shows 10,296 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where MIR6859-4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6859-4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6859-4 survival associations across molecular data types. MIR6859-4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6859-4 RNA expression–survival associations across cancer types. High MIR6859-4 expression shows unfavorable associations in KIRC, CHOL, ESCA, COAD and ACC, but favorable associations in LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR6859-4 RNA expression.
This table summarizes MIR6859-4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6859-4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6859-4 shows lower tumor expression in COAD and higher tumor expression in LIHC, HNSC, KIRC and CHOL. The LIHC box plot shows higher MIR6859-4 RNA expression in tumor versus normal tissue (log2 FC = +0.318, t-test p = .010).
This table shows molecular features associated with MIR6859-4 in patient tissues and cancer cell lines. In patient samples, MIR6859-4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
